Two months after the FDA issued a safety alert on Pfizer's Chantix, the company in January agreed to update labeling to warn patients about the potential for serious neuropsychiatric symptoms.
Congress has finally passed the Right to Try Act, but does it go far enough?
The government agency released its latest guidance this week.
11 questions for the GW CEO on the watershed moment.
